Anlotinib plus Sintilimab
Phase 2Monoclonal antibody
Anlotinib plus Sintilimab is one of 7 small molecule programs targeting Pheochromocytoma. It is currently in Phase 2.
2
Indications
6
Total Trials
3
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
4 competitors in Pheochromocytoma
#DrugCompanyPhaseTrials
1Welireg
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Zanzalintinib
Merck & Co.Phase 2
Anlotinib plus Sintilimab
SSun Yat-sen University
Phase 2
Lu-177-DOTATATE
NNational Cancer Institute (NCI)
Phase 2
Ga-68-DOTATATE
WWeill Medical College of Cornell University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Soft-tissue Sarcoma1 trial
Endometrial Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anlotinib plus Sintilimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 2[1]
- Company
- SSun Yat-sen University